Hepatitis Journal Options – Volume 4, Issue 1

Stay up to date with the current medical literature through a CME-certified learning module including CCO’s Capsule Summaries of the most relevant recently published articles with accompanying Expert Commentaries and downloadable slidesets.

Topics include:

• Telaprevir Plus Peginterferon/Ribavirin Significantly Improves SVR in Genotype 1 HCV Previous Nonresponders
• Treatment Extension in Genotype 1/4 HCV Patients With Slow Virologic Response to Peginterferon/Ribavirin
• Hepatic Expression of Interferon-Stimulated Genes in Chronic Hepatitis C
• Decrease in Serum HBsAg During Entecavir Treatment in HBeAg-Positive HBV-Infected Patients
• Tenofovir Monotherapy in HBV-infected Patients With Previous Lamivudine and Adefovir Resistance
• 5-Year Durability of Response to Peginterferon alfa-2b Plus Lamivudine in Asian HBeAg-Positive HBV-Infected Patients
• Rifaximin for Recurrent Hepatic Encephalopathy in Remission
• Vitamin E for Nonalcoholic Steatohepatitis in Nondiabetic Patients

CCO Hepatitis Stay Tuned 

Bimonthly CME-certified audio Podcasts, each supported by a variety of online resources.

HBV Treatment and Everyday Realities —Volume 1, Edition 2 Video and audio podcasts of hot topics and practical strategies in the management, treatment, and care of patients with chronic viral hepatitis, including those with advanced liver disease.  Click here to start.

Keeping the Core: Assessing the Role of Pegylated Interferons and Emerging Novel Interferons in HCV Treatment 

Interactive Virtual Presentation with downloadable slides.

CME-Certified Interactive Virtual Presentation:

Keeping the Core: Assessing the Role of Pegylated Interferons and Emerging Novel Interferons in HCV Treatment Michael P. Manns, MD; Peter Ferenci, MD; and David R. Nelson, MD, review the efficacy and safety profiles of approved and late-phase interferons as well as the role of interferons in the emerging area of targeted antiviral agents.

Downloadable Slideset:

Keeping the Core: Assessing the Role of Pegylated Interferons and Emerging Novel Interferons in HCV Treatment Peter Ferenci, MD; Michael P. Manns, MD; and David R. Nelson, MD; discuss the safety and efficacy of approved and investigational interferons and their potential future role with direct-acting antivirals.

Staying the Course: Patient Adherence Strategies in the Era of New Frontline HBV Therapies

Participate in an Interactive Virtual Presentation and download slides and a worksheet for use in your own practice.

Interactive Virtual Presentation:

Optimizing Adherence to Therapy in Patients With Chronic Hepatitis B

Downloadable Worksheet: HBV Treatment Adherence Worksheet

2010 Annual Meeting of the European Association for the Study of the Liver

CCO's independent conference coverage of the 2010 Annual Meeting of the European Association for the Study of the Liver includes Capsule Summaries of key presentations, as well as Expert Analyses, and audio Expert Highlights that focus on key issues highlighted at the conference.

From Podium to Practice: Clinical Impact of New HCV Data From Vienna
Paul Y. Kwo, MD; Jean-Michel Pawlotsky, MD, PhD; Stefan Zeuzem, MD

Management of HBV, Advanced Liver Disease, and Other Related Complications
Paul Martin, MD

Lessons Learned: Best Practices in the Management of Patients Who Previously Failed HCV Treatment 

This treatment update explores the latest data on available therapeutic options and management strategies for the approximately 40% to 60% of patients infected with genotype 1 HCV who experience treatment failure to frontline therapy.

Now Available!

CME-Certified Interactive Virtual Presentation:

Downloadable CCO Slideset:

Lessons Learned: Best Practices in the Management of Patients Who Previously Failed HCV Treatment Brian L. Pearlman, MD, FACP, discusses management strategies for patients who have failed HCV treatment.

Hepatitis Journal Options - Volume 3, Issue 3 

Stay up to date with the current medical literature through a CME-certified learning module including CCO’s Capsule Summaries of the most relevant recently published articles with accompanying Expert Commentaries and downloadable slidesets.

Topics include:

• Genetic Link to Therapeutic Response Identified Among HCV-Infected Individuals
• Peginterferon alfa-2a and alfa-2b Produce Similar SVR Rates
• Weight Loss Can Alter HCV Liver Disease Progression
• Metabolic Factors That Predict RVR to Peginterferon/Ribavirin in HCV Patients
• Short-Duration Therapy for Genotype 1 Treatment-Naive HCV Patients
• High ALT and HBeAg-Negative, HBsAg-Positive Disease
• Chronic Hepatitis B: A Predictor of Long-term Response to Peginterferon Identified
• Lactulose Prophylaxis for the Prevention of Hepatic Encephalopathy Recurrence

Smoother Waters Ahead? New Directions in the Management of HCV 

In this new Treatment Update, CCO’s expert faculty members assess the scale of the current and estimated future HCV epidemic, review the latest data from recent and ongoing clinical trials investigating the use of targeted antiviral therapies (STAT-Cs) for the management of HCV infection, and explore how these findings may impact future HCV treatment paradigms.

Now Available!

CME-Certified Interactive Virtual Presentation:

Smoother Waters Ahead? New Directions in the Management of HCV Stefan Zeuzem, MD, provides insights into the magnitude of the HCV epidemic and current challenges when treating patients with HCV infection in this Interactive Virtual Presentation. He also reviews data from recent and ongoing clinical trials of STAT-C agents in late clinical development and their potential impact on HCV management. Participants are polled on practical issues in current and near future HCV treatments and can compare their results to their colleagues.

Downloadable CCO Slideset:

Smoother Waters Ahead? New Directions in the Management of HCV Downloadable slideset for use in your own noncommercial presentations highlights key data on the magnitude of the HCV epidemic and data from recent ongoing clinical trials and the potential impact on HCV management of STAT-C agents in late clinical development.

Downloadable Worksheets:

Genotype 1/4 HCV Treatment Monitoring Chart This worksheet allows you to conveniently record HCV RNA and key laboratory measurements that should be monitored before, during, and after HCV therapy of genotype 1/4 patients.

Genotype 2/3 HCV Treatment Monitoring Chart This worksheet allows you to conveniently record HCV RNA and key laboratory measurements that should be monitored before, during, and after HCV therapy of genotype 2/3 patients.

Beyond the Tip of the Iceberg: Strategies to Ensure Optimal HBV Screening, Diagnosis, and Initial Therapy

This treatment update delivers an overview of current best practices for screening and diagnosing patients with chronic hepatitis B and provides a detailed analysis of the safety, efficacy, durability, and potency of approved state-of-the-art options for initiating HBV treatment.

Now Available!

Downloadable CCO Slideset:

Beyond the Tip of the Iceberg: Strategies to Ensure Optimal HBV Screening, Diagnosis, and Initial Therapy Downloadable slides for use in your own noncommercial presentations highlight key data on selecting patients for HBV screening and evaluation and optimizing first-line treatment.

Downloadable Worksheet:

HBV Screening and Evaluation Information Sheet This downloadable information sheet highlights the key patient populations for HBV screening and outlines the initial steps in diagnosis and evaluation.

Hepatitis Annual Update 2009

Clinical Care Options' Hepatitis Annual Update offers the latest information across a wide range of issues for the optimal clinical management of your patients. Expert faculty members prepared the following CME/CE-certified educational modules and a downloadable slideset that are now available on the CCO Web site:

Now Available!

CME/CE-Certified Modules:

HBV Infection: Deciding Who and When to Treat  Anna S. F. Lok, MD, discusses factors to consider when evaluating patients with chronic hepatitis B infection for initiating treatment.

Benefits and Risks of HBV Therapy  Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, reviews the benefits and risks for hepatitis B management using currently available therapeutic agents.

Mechanisms of Response and Nonresponse to HCV Treatment  Raymond T. Chung, MD, reviews the mechanisms of response and nonresponse in HCV treatment, including fixed and modifiable factors.

Update on Investigational HCV Agents  Jean-Michel Pawlotsky, MD, PhD, discusses how insights into the virology of HCV have unraveled several targets for potential novel therapeutics.

Update in the Diagnosis and Management of Decompensated Cirrhosis  Timothy Morgan, MD, reviews current treatment guidelines for the management of advanced liver disease and its complications in the context of recent clinical trial data.

Downloadable PowerPoint Slideset:

Hepatitis Annual Update 2009  Review the latest data on HBV and HCV management, as well as the diagnosis and management of decompensated cirrhosis.

Understanding and Implementing the AASLD’s 2009 Practice Guidelines on the Diagnosis, Management, and Treatment of Hepatitis C: An Update

This comprehensive Management Series provides an in-depth analysis of the updated 2009 AASLD recommendations for diagnosing and managing treatment-naive and treatment-experienced patients with chronic hepatitis C. Specific strategies for optimizing therapy according to HCV genotype and on-treatment virologic response are discussed as are tailored approaches for managing special patient populations.

Now Available!

CME-Certified Interactive Virtual Presentations:

Downloadable CCO Slidesets:

	Hepatitis C Testing and Counseling: The Gateway to Treatment In this downloadable slideset, David L. Thomas, MD, MPH, discusses the importance of HCV testing, as it is the first step in the management and treatment of HCV infection.
	Initial HCV Management, Treatment and Monitoring In this downloadable slideset, John G. McHutchison, MD, FRACP, provides an update on the initial management, treatment, and monitoring of patients with hepatitis C.
	Management and Treatment of Special Populations of HCV-Infected Patients In this downloadable slideset, Ira M. Jacobson, MD, reviews the AASLD guideline recommendations for the treatment of special populations of HCV-infected persons.

CME-Certified Interactive Case Challenges:

Downloadable Worksheet:

HCV Management Algorithm Based on the 2009 AASLD Practice Guideline “Diagnosis, Management, and Treatment of Hepatitis C: An Update” This quick reference guide to the AASLD HCV Practice Guideline Update condenses the recommendations into a concise chronic HCV infection treatment algorithm.

Hepatitis Journal Options - Volume 3, Issue 2 

Stay up to date with the current medical literature through a CME-certified learning module and CCO’s capsule summaries of the most relevant recently published articles with accompanying Expert Commentaries and downloadable slidesets.

Topics include:

• Telaprevir for chronic HCV genotype 1 infection
• Prolonged HCV therapy with low-dose peginterferon
• HCC in hepatitis C–related advanced liver disease
• Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin: DIRECT results
• Chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, ribavirin
• Tenofovir vs adefovir for chronic hepatitis B
• Early serum HBsAg drop and SVR in HBeAg-negative patients
• Rifaximin for hepatic encephalopathy
• Effect of fatigue on driving skills in hepatic encephalopathy patients
  
  

HBV Treatment: What to Start?

CCO’s expert faculty members discuss the latest clinical data and best practices for selecting optimal initial HBV therapy, including a review of different initial management strategies for HBeAg-positive and HBeAg-negative patients with chronic HBV infection.

Now Available!

CME-Certified Module:

HBV Treatment: What to Start? Robert G. Gish, MD, describes the latest data and reviews the most recent guidelines on the optimal selection of first-line therapy for patients with chronic hepatitis B infection.

Downloadable CCO Slideset:

HBV Treatment: What to Start? Download slide highlights from the CME-certified module on initial HBV therapies for self study and use in your own noncommercial presentations.

CME-Certified Interactive Case Challenges:

Managing Initial Treatment for an Asian American Patient With HBeAg-Positive Chronic Hepatitis B Learn about frontline regimen selection and on-treatment management of an HBeAg-positive patient and apply this learning with Albert D. Min, MD, in this Interactive Case Challenge.

Management of Initial HBV Therapy for an HBeAg-Negative Patient Attempt this Interactive Case Challenge and learn strategies for frontline regimen selection and on-treatment management of patients with HBeAg-negative chronic HBV infection with Calvin Q. Pan, MD, FACP, FACG.

Multidisciplinary Strategies in the Management of Patients With Hepatocellular Carcinoma: A Video Roundtable

Expert faculty members review and explore regional and systemic treatment strategies for the clinical management of patients with hepatocellular carcinoma.

Now Available!

Video Panels:

• Hepatitis C Advanced Practice Curriculum 2009
  Through 3 Interactive Virtual Presentations, CCO’s expert faculty members review recent data and discuss critical aspects of HCV disease management, including the importance of patient quality of life, topics pertaining to patient retreatment, and strategies for minimizing cirrhosis and liver disease progression.
  

• 2009 American Association for the Study of Liver Diseases
  
  
• 2009 Annual Meeting of the European Association for the Study of the Liver

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

• Management of a Genotype 1 HCV Patient in a Methadone Maintenance Program
  
  
  
• Management of an HCV-Infected Compensated Cirrhotic Patient With Moderate Alcohol Use
  
  
  
• Management of an HCV-Infected Black Woman With Delayed Diagnosis and Treatment
  
   

Topics

• Fibrosis and Cirrhosis
• HBV
• HCV
• Hepatocellular Carcinoma
• HIV Coinfection
• Nash, ALD, etc.
• Other Hepatitis Viruses
• Transplantation

Resources

• Advanced Search
• Case Challenges
• Animations
• Live Events
• Slide Download Library
• Interactive Tools
• Bookstore

PROVE 3: SVR Improved With Telaprevir Combined With Peginterferon alfa-2a/Ribavirin Therapy in Genotype 1 HCV Patients Failing Previous Regimen; 1-Year Durability Demonstrated

Response rates were significantly higher with telaprevir/peginterferon/ribavirin regimens vs peginterferon/ribavirin alone in previous nonresponders or relapsers to peginterferon/ribavirin treatment.

Click here for related capsule summaries